In addition to providing a rationale to target LH2 in cancer, these findings support a paradigm in which LH2 functions as a regulatory switch that controls the relative abundance of distinct types of collagen cross-links that influence the metastatic fate of tumor cells. The gene discussed is PLOD2; the disease is cancer.